Business Context and Reporting Period
This Form 8-K, dated September 15, 2022, is filed by Mana Capital Acquisition Corp. (the "Registrant") regarding its proposed business combination with Cardio Diagnostics, Inc. ("Cardio"). Upon closing, Mana Capital will change its name to Cardio Diagnostics Holdings, Inc. The filing reports the execution of a First Amendment to the Merger Agreement originally entered into on May 27, 2022.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either Mana Capital or Cardio. This document focuses on the legal and structural amendments to the merger agreement rather than operational financial performance.
Material Changes
The primary material change disclosed is the execution of the First Amendment to the Merger Agreement on September 15, 2022. Key modifications include:
- Incentive Plan Increase: The number of shares reserved under the Cardio Diagnostics Holdings, Inc. 2022 Incentive Plan has been increased to 3,265,516 shares.
- University of Iowa Research Foundation (UIRF) Consideration: Upon closing, the UIRF will be issued shares of common stock equal to 1% of the aggregate merger consideration issuable to Cardio stockholders. This replaces the UIRF's previous equity rights in Cardio under its license agreement.
Guidance, Outlook, and Risks
Outlook and Status: The Merger Agreement remains in full force and effect subject to the satisfaction or waiver of closing conditions. Mana Capital has filed a registration statement on Form S-4 containing proxy materials for stockholder approval. The definitive proxy statement will be mailed to stockholders once the Form S-4 is declared effective.
Risks and Contingencies: The filing includes extensive forward-looking statements and identifies significant risks that could cause the business combination to fail or results to differ from expectations, including:
- Failure to obtain stockholder approval or satisfy closing conditions.
- Receipt of unsolicited offers for alternative transactions.
- Inability to list the post-acquisition company on the Nasdaq Stock Market.
- Disruption of current operations and inability to retain key employees.
- Intellectual property protection challenges and market penetration risks.
- Impact of the COVID-19 pandemic and changes in applicable laws.
Investor Verification Checklist
- Review the Form S-4 (File No. 333-265308) for detailed financial projections and risk factors.
- Verify the final terms of the 1% equity issuance to the University of Iowa Research Foundation.
- Confirm the status of the Form S-4 effectiveness and the timeline for the stockholder vote.
- Monitor for any unsolicited offers or legal proceedings that could terminate the Merger Agreement.
- Check the Nasdaq listing status requirements for the post-combination entity.